2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Profiling, Treatment Considerations, Supportive Care, Biological Therapies, Gene Therapy, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6201 Burden and recurrence of acute kidney injury in pediatric sickle cell disease using kdigo creatinine criteria

Abraham Haimed, MD, Vanaja Danda2, Alexis A. Thompson, MD MPH3
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background

Acute kidney injury (AKI) is an increasingly recognized complication of sickle cell disease (SCD) and has been associated with chronic kidney disease (CKD) and increased morbidity in adults. Reported prevalence in children ranges widely, from 1.1% to 48.7%, largely because prior studies have been limited to hospitalized patients or to individual acute complications and may not reflect the true burden. In adults with sickle cell anemia, KDIGO AKI stage has been associated with subsequent CKD progression independent of age and baseline eGFR supporting attention to AKI severity as well as occurrence. We sought to characterize the prevalence, recurrence, severity, and clinical context of AKI in a large pediatric SCD cohort using KDIGO creatinine criteria.

Methods

We performed a retrospective single-center cohort study of pediatric patients with a physician-attested sickle cell disease diagnosis from the Children's Hospital of Philadelphia cohort within the ASH Research Collaborative® (ASH RC) Data Hub. The ASH RC Data Hub is a high-quality, real-world clinical data resource that collects data from hospitals across the United States to accelerate SCD research. AKI was identified using KDIGO creatinine criteria, excluding urine output criteria. Rather than applying a single fixed baseline, each serum creatinine value was compared with the patient's most recent prior outpatient measurement within the preceding 365 days, allowing the reference creatinine to evolve over follow-up as additional measurements accrued. Separate AKI events were defined using a pre-specified washout period. Algorithm-identified AKI events underwent manual validation to confirm classification accuracy. AKI events were assessed for temporal association with vaso-occlusive episodes, acute chest syndrome, splenic sequestration, and priapism occurring within seven days of the AKI event.

Results

The cohort included 1,701 pediatric patients with a physician-attested SCD diagnosis. Overall, 280 patients (16.5%) experienced at least one AKI episode; among these patients, median age was 15 years, 144 (51.4%) were male, and the SCD subtype was HbSS in 220 (78.6%). Among affected patients, 125 (44.6%) experienced recurrent AKI, including 59 (21.1%) with two episodes and 66 (23.6%) with three or more episodes, accounting for 769 AKI events overall. Stage 1 AKI was the highest stage in 233 patients (83.2%), whereas 31 (11.1%) and 16 (5.7%) patients reached Stage 2 and Stage 3 AKI, respectively. Most events arose in ambulatory care: of 731 events with a classified visit type, 595 (81.4%) occurred at outpatient visits. Overall, 200 of 769 AKI events (26%) occurred within seven days of a predefined SCD complication, whereas 569 (74%) occurred outside these predefined complication windows.

Conclusions

AKI affected approximately one in six pediatric patients with SCD, and nearly half of affected patients experienced recurrent AKI. Although most patients experienced Stage 1 AKI, approximately 17% of affected patients reached Stage 2 or Stage 3. The large majority of AKI events were identified at outpatient visits rather than during hospitalization, and nearly three-quarters occurred outside predefined acute SCD complication windows, suggesting that AKI in pediatric SCD extends beyond traditionally recognized acute presentations and inpatient settings. These findings support systematic surveillance for AKI across pediatric SCD care and provide a framework for future multicenter studies evaluating risk factors and long-term kidney outcomes.

The ASH Research Collaborative provided data for this analysis. The views expressed in this publication are solely of the authors and do not represent the opinion of the ASH Research Collaborative or the American Society of Hematology.

Abraham Haimed, MD: No relevant conflicts of interest to declare.